Based on the Sage Therapeutic stock forecast from 10 analysts, the average analyst target price for Sage Therapeutic is USD 10.95 over the next 12 months. Sage Therapeutic’s average analyst rating is Hold . Stock Target Advisor’s own stock analysis of Sage Therapeutic is Slightly Bearish, which is based on 3 positive signals and 4 negative signals. At the last closing, Sage Therapeutic’s stock price was USD 7.37. Sage Therapeutic’s stock price has changed by +6.50% over the past week, -4.53% over the past month and -52.85% over the last year.
No recent analyst target price found for Sage Therapeutic
No recent average analyst rating found for Sage Therapeutic
Company Overview Sage Therapeutic
Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes brain health medicines. The company offers ZURZUVAE, a neuroactive steroid positive allosteric modulator of GABA receptors targeting synaptic and extrasynaptic GABA receptors for the treatment of postpartum depression in adults. Its product pipeline also includes SAGE-324, a novel GABA receptor positive allosteric modulator for chronic oral dosing, including seizures in developmental and epileptic encephalopathies; and SAGE-319, an extrasynaptic-preferring GABA receptor positive allosteric modulator PAM for treating behavioral symptoms associated with neurodevelopmental disorders. In addition, the company is developing various product candidates, including SAGE-817 and SAGE-039 for the treatment of acute and chronic brain health disorders, including work on allosteric modulation of the GABA and NMDA receptor systems in the brain, as well as NMDA receptor negative allosteric modulator focusing on the treatments for neurodevelopmental disorders. The company was formerly known as Sterogen Biopharma, Inc. and changed its name to Sage Therapeutics, Inc. in September 2011. Sage Therapeutics, Inc. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts. Read Less
Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes brain health medicines. The company offers ZURZUVAE, a neuroactive steroid positive allosteric modulator of GABA receptors targeting synaptic and extrasynaptic GABA receptors for the treatment of po...Read More
Frequently Asked Questions About Sage Therapeutic (SAGE) Stock
Based on ratings from 10 analysts Sage Therapeutic's stock is Hold . Stock Target Advisor's fundamental analysis is Slightly Bearish. The stock has 6 buy, 2 sell and 13 hold ratings.
Unfortunately we do not have enough data on SAGE's stock to indicate if its a good dividend stock.
Based on targets from 10 analysts, the average taret price for SAGE is USD 10.95 over the next 12 months. The maximum analyst target price is USD 26 while the minimum anlayst target price is USD 4.
SAGE stock's Price/Earning ratio is 3.09.
Our analysis grades SAGE stock's Price / Earning ratio at F. This means that SAGE stock's Price/Earning ratio is above 42.00000000000001% of the stocks in the Biotechnology sector in the NSD exchange.
Based on this SAGE may be fairly valued for its sector
The last closing price of SAGE's stock was USD 7.37.
The most recent market capitalization for SAGE is USD 0.50B.
Based on targets from 10 analysts, the average taret price for SAGE is projected at USD 10.95 over the next 12 months.
This means that SAGE's stock price may go up by +48.61% over the next 12 months.
We can't find any ETFs which contains Sage Therapeutic's stock.
As per our most recent records Sage Therapeutic has 353 Employees.
Sage Therapeutic's registered address is 55 Cambridge Parkway, Cambridge, MA, United States, 02142.
You can get more information about it from Sage Therapeutic's website at https://www.sagerx.com.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Superior capital utilization
The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.
High market capitalization
This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.
Superior Earnings Growth
This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.
What not to like
Below median dividend returns
The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.
Poor risk adjusted returns
This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.
Negative cashflow
The company had negative total cash flow in the most recent four quarters.
Negative free cash flow
The company had negative total free cash flow in the most recent four quarters.
Frequently Asked Questions About Sage Therapeutic (SAGE) Stock
Based on ratings from 10 analysts Sage Therapeutic's stock is Hold . Stock Target Advisor's fundamental analysis is Slightly Bearish. The stock has 6 buy, 2 sell and 13 hold ratings.
Unfortunately we do not have enough data on SAGE's stock to indicate if its a good dividend stock.
Based on targets from 10 analysts, the average taret price for SAGE is USD 10.95 over the next 12 months. The maximum analyst target price is USD 26 while the minimum anlayst target price is USD 4.
SAGE stock's Price/Earning ratio is 3.09.
Our analysis grades SAGE stock's Price / Earning ratio at F. This means that SAGE stock's Price/Earning ratio is above 42.00000000000001% of the stocks in the Biotechnology sector in the NSD exchange.
Based on this SAGE may be fairly valued for its sector
The last closing price of SAGE's stock was USD 7.37.
The most recent market capitalization for SAGE is USD 0.50B.
Based on targets from 10 analysts, the average taret price for SAGE is projected at USD 10.95 over the next 12 months.
This means that SAGE's stock price may go up by +48.61% over the next 12 months.
We can't find any ETFs which contains Sage Therapeutic's stock.
As per our most recent records Sage Therapeutic has 353 Employees.
Sage Therapeutic's registered address is 55 Cambridge Parkway, Cambridge, MA, United States, 02142.
You can get more information about it from Sage Therapeutic's website at https://www.sagerx.com.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for SAGE !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
